-
Notifications
You must be signed in to change notification settings - Fork 0
Commit
This commit does not belong to any branch on this repository, and may belong to a fork outside of the repository.
Add: create deep vein thrombosis management question with options and…
… explanations
- Loading branch information
Showing
1 changed file
with
41 additions
and
0 deletions.
There are no files selected for viewing
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
Original file line number | Diff line number | Diff line change |
---|---|---|
@@ -0,0 +1,41 @@ | ||
--- | ||
id: HEMA001 | ||
specialty: hematology | ||
topic: thrombosis | ||
difficulty: medium | ||
tags: [dvt, treatment, riskStratification, pharmacology] | ||
created: 2025-01-02 | ||
lastUpdated: 2025-01-02 | ||
--- | ||
|
||
# Deep Vein Thrombosis Management | ||
|
||
## Question | ||
A 52-year-old man presents with a left lower extremity DVT confirmed by Doppler ultrasound. He has no recent surgery or immobilization, and no known malignancy. Which management is most appropriate? | ||
|
||
## Options | ||
| Option | Description | | ||
|--------|--------------------------------------------------------| | ||
| A) | Compression stockings only | | ||
| B) | Low molecular weight heparin (LMWH) for 3 months | | ||
| C) | Oral factor Xa inhibitor for at least 3-6 months | | ||
| D) | IVC filter placement + indefinite anticoagulation | | ||
| E) | Thrombolytic therapy + extended LMWH | | ||
|
||
<details> | ||
<summary>View Answer</summary> | ||
|
||
## Correct Answer | ||
C | ||
|
||
## Explanation | ||
1. Unprovoked DVT generally requires at least 3 months of anticoagulation. | ||
2. Factor Xa inhibitors (e.g., rivaroxaban/apixaban) are often first-line. | ||
3. Extended therapy may be necessary if the patient’s bleeding risk is low. | ||
4. Compression stockings help with symptom control but are not definitive. | ||
5. IVC filters are for contraindications or recurrent VTE on adequate therapy. | ||
|
||
## References | ||
- 2021 ACCP Guidelines for Antithrombotic Therapy | ||
- NEJM 2018: "New Oral Anticoagulants for VTE" | ||
</details> |